Precision Targeting. Built for Today’s Payloads.
We are advancing a proprietary targeting platform designed to enable selective delivery across today’s leading cancer therapeutic payloads.
Apik Bio is currently operating in stealth mode. We welcome dialogue with investors and strategic partners.
Our Platform
Apik Bio is developing a proprietary precision targeting platform designed to improve how therapeutic payloads reach their intended site of action.
Our approach is engineered to enhance selectivity and target engagement, with potential applicability across multiple modalities, including radiopharmaceuticals, antibody-drug conjugates, and biologics.
Designed for selective delivery
Applicable across multiple payload classes
Built on proprietary targeting architecture
Derived from foundational research conducted in leading academic institutions.
Led by a team with experience spanning biotechnology development, clinical practice, and translational research.
Advancing through a focused, disciplined strategy with a clear path to strategic partnership.
Why Precision Targeting Matters
Many therapeutic approaches are limited by insufficient selectivity and off-target effects.
A precision targeting layer has the potential to improve efficacy, expand therapeutic windows, and unlock the full value of modern payloads.
Investor and collaboration inquiries
We welcome conversations with investors and strategic partners.
If you are interested in learning more, we invite you to connect.